Rakovina Therapeutics Stock Price To Earning
| RKV Stock | CAD 0.08 0.01 23.08% |
Rakovina Therapeutics fundamentals help investors to digest information that contributes to Rakovina Therapeutics' financial success or failures. It also enables traders to predict the movement of Rakovina Stock. The fundamental analysis module provides a way to measure Rakovina Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rakovina Therapeutics stock.
Rakovina | Price To Earning |
Rakovina Therapeutics Company Price To Earning Analysis
Rakovina Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Rakovina Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Rakovina Therapeutics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all Canada stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Rakovina Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 7.21 M | ||||
| Shares Outstanding | 90.29 M | ||||
| Shares Owned By Insiders | 31.94 % | ||||
| Number Of Shares Shorted | 904 | ||||
| Price To Book | 1.90 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.61 M) | ||||
| Cash And Equivalents | 4.37 M | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (1.86 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Beta | 0.046 | ||||
| Market Capitalization | 7.22 M | ||||
| Total Asset | 5.15 M | ||||
| Retained Earnings | (10.93 M) | ||||
| Working Capital | 477.88 K | ||||
| Net Asset | 5.15 M |
About Rakovina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rakovina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rakovina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rakovina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.